Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | HCAR3 | P49019 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30001328 | 1.00 | CASP6 (0.70) | CASP6TSHRLMNATDP1ATM | |
| Hydrochloric Acid SCHEMBL5568198 | 0.98 | CASP6 (0.68) | CASP6TSHRLMNATDP1ATM | |
| SCHEMBL24994 | 0.85 | CASP6 (0.70) | CASP6TSHRLMNAHCAR3MEN1 | |
| SCHEMBL6648516 | 0.84 | HCAR3 (0.54) | CASP6TSHRLMNAHCAR3 | |
| SCHEMBL30149157 | 0.84 | ATM (0.56) | CASP6TSHRLMNATDP1ATM | |
| SCHEMBL275422 | 0.84 | ATM (0.56) | CASP6TSHRLMNATDP1ATM | |
| SCHEMBL31176043 | 0.84 | PARP1 (0.60) | CASP6TSHRLMNATDP1ATM | |
| SCHEMBL11248434 | 0.84 | ATM (0.56) | CASP6TSHRTDP1ATMMEN1 | |
| SCHEMBL1937077 | 0.84 | PARP1 (0.60) | CASP6TSHRLMNATDP1ATM | |
| SCHEMBL10903666 | 0.83 | MAPK1 (0.68) | CASP6TSHRLMNATDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 936 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| CN-118812209-A | Preparation method of polyvinyl alcohol emulsion modified cement paste generated in situ | 海南大学 | 2024-10-22 | — | — | CN | claimed |
| CN-118621569-A | Polyvinyl alcohol fiber surface acetalation modification method | 海南大学 | 2024-09-10 | — | — | CN | claimed |
| CN-117945917-A | Preparation method of 3-fluoro-4-nitrobenzoic acid | 衢州康鹏化学有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117447327-A | Preparation method of 3-fluoro-4-nitrobenzoic acid | 上海万溯药业有限公司 | 2024-01-26 | — | — | CN | claimed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| CN-112266328-B | Synthetic route and preparation method of 3-fluoro-4-nitrobenzaldehyde | 郑州萃智医药科技有限公司 | 2023-11-03 | — | — | CN | claimed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | claimed |
| CN-112851646-B | Preparation method of tergolian prazan | 中国医学科学院药物研究所 | 2023-06-13 | — | — | CN | claimed |
| EP-4127157-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2022267470-A1 | SEH INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE COMPOSITION THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 沈阳药科大学 | 2022-12-29 | — | — | WO | claimed |
| WO-2022072560-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2021194908-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2021-09-30 | — | — | WO | claimed |
| CN-112851646-A | Preparation method of Tegolrazan | 中国医学科学院药物研究所 | 2021-05-28 | — | — | CN | claimed |
| CN-112266328-A | Synthetic route and preparation method of 3-fluoro-4-nitrobenzaldehyde | 郑州萃智医药科技有限公司 | 2021-01-26 | — | — | CN | claimed |
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | MINDRANK AI LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-4629811-A | 3-sulfonylamino-4-aminobenzophenone derivatives | ELI LILLY AND COMPANY (US) | 1986-12-16 | — | — | US | disclosed |
| US-4483986-A | 4-Nitrobenzophenone compounds | ELI LILLY AND COMPANY (US) | 1984-11-20 | — | — | US | disclosed |
| EP-0093590-A1 | Process for the preparation of sulfonylamino benzophenones | ELI LILLY AND COMPANY (US) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | BAX, BCL2, BAK1 | CASP6 22/4885TSHR 3456/4885LMNA 76/4885 |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | GLP1R, GIPR, GCGR | CASP6 1135/4885TSHR 32/4885LMNA 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.